Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
about
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancerStructural diversity of eukaryotic membrane cytochrome p450sAndrogen biosynthesis in castration-resistant prostate cancerStructures of human steroidogenic cytochrome P450 17A1 with substratesCytochrome P450 17A1 Interactions with the FMN Domain of Its Reductase as Characterized by NMRPromising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 InhibitorsStructural insights into the function of steroidogenic cytochrome P450 17A1Enzymatic and Nonenzymatic Electrochemical Interaction of Abiraterone (Antiprostate Cancer Drug) with Multiwalled Carbon Nanotube BioelectrodesTargeting Neuroblastoma Cell Surface Proteins: Recommendations for Homology Modeling of hNET, ALK, and TrkBHuman cytochrome P450 17A1 conformational selection: modulation by ligand and cytochrome b5.TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency.CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Novel drugs targeting the androgen receptor pathway in prostate cancer.The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.Recent Structural Insights into Cytochrome P450 Function.Catalytically relevant electrostatic interactions of cytochrome P450c17 (CYP17A1) and cytochrome b5.A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone.Structural and kinetic basis of steroid 17α,20-lyase activity in teleost fish cytochrome P450 17A1 and its absence in cytochrome P450 17A2.The diverse chemistry of cytochrome P450 17A1 (P450c17, CYP17A1).Mechanistic Scrutiny Identifies a Kinetic Role for Cytochrome b5 Regulation of Human Cytochrome P450c17 (CYP17A1, P450 17A1).Incorporation of charged residues in the CYP2J2 F-G loop disrupts CYP2J2-lipid bilayer interactions.Enzyme Tunnels and Gates As Relevant Targets in Drug Design.Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular DynamicsMinor activities and transition state properties of the human steroid hydroxylases cytochromes P450c17 and P450c21, from reactions observed with deuterium-labeled substrates.Unveiling the crucial intermediates in androgen production.Substrate-modulated cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR.Cytochromes p450: roles in diseasesRecent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.Functional studies of N-terminally modified CYP2J2 epoxygenase in model lipid bilayersMolecular pathways: Inhibiting steroid biosynthesis in prostate cancer.Phosphorylation of human cytochrome P450c17 by p38α selectively increases 17,20 lyase activity and androgen biosynthesis.Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.Differential hydrogen bonding in human CYP17 dictates hydroxylation versus lyase chemistryAKR1C3 as a target in castrate resistant prostate cancerCorrelating structure and function of drug-metabolizing enzymes: progress and ongoing challenges.Resonance Raman spectroscopy reveals that substrate structure selectively impacts the heme-bound diatomic ligands of CYP17.Current physico-biochemistry in steroid research and status of structural biology for steroid-converting enzymes.Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions.New reactions and products resulting from alternative interactions between the P450 enzyme and redox partners.
P2860
Q27010542-EC69AC92-9D26-4C1E-9055-F93C3F3F19AEQ27025716-EE103AED-01F2-43FA-8028-7660EB4A77F8Q27026044-B06A50E6-47AE-41EC-A144-731B95937E9FQ28249471-47050152-030F-4E20-BFAF-265114011C53Q28271636-4577A445-E029-4599-9334-5F6F296E69FBQ28277042-76A14DD7-6AF6-455B-8750-E873FE9C8EF2Q28278089-B0A11BFF-FE33-41AF-A566-42B9B5869E34Q28818516-FB3813DE-FCCF-466E-8BDC-844CE191F4FEQ28818744-D7BD5ECE-8AD2-4393-825C-3CCECE10FB13Q30360659-629F13FF-840C-4393-9C21-8A3DC676E59FQ30554439-77EEFA52-E131-4342-97BA-73F556DA4363Q33998980-1CB0D177-029F-4751-91ED-DE8F67C54F89Q34387852-FDEBE05A-457F-49B2-AA8D-456AB17495C1Q34395777-1F6D49BC-4AFA-4D65-ABAF-F7F452EAAA52Q34525556-56B0B821-C697-4A0A-B17C-25CF58D87BA5Q34529849-47C7EE97-C825-445D-8AAC-3FCD06E384ADQ34634130-A998833F-1DDE-40F1-9D86-DD91EAEFC4B7Q34746876-ADAF9AF9-B1C7-4E4D-9904-E5F9387FD32EQ35055474-39AE5348-8937-4D63-B1F9-27A248DF63E5Q35685356-9DB112D1-C5A0-4E3B-B8FF-CB31F1818902Q35846946-B377E157-79F9-406E-B54B-95D26FABCDF3Q36025678-AD3818BD-F3BE-4F22-A3D6-718BC62ECD5BQ36221405-D4DB91A8-9D5B-4A32-96CE-01F311B3EC28Q36297428-AAC005EA-749B-44F7-BD99-6E41F57315D8Q36317595-F9366CCA-88C3-436C-A598-6BC2FAA1689DQ36435371-E6FC6C96-07D6-4211-A44D-B1F8BD1FB346Q36910210-481607D8-104B-4DD8-B8C9-DF86E6A98ECCQ36928922-6BE0AB96-9488-4AEB-A080-A9600467A5B2Q37025619-4AD4C68A-4269-4BAC-9073-59AA495E63EFQ37034584-5AE70253-BEFE-4A9B-88F7-914CB1613EC2Q37076775-2D5A24A4-A408-4040-ACA5-882DD9E0A43CQ37099736-4BE95E5C-5EF9-4FA8-8B6A-000B8315060BQ37134564-45B686FA-2E7C-4DC1-8D5A-DCA2467DCC3AQ37169659-42BBCAB3-D896-4DFC-959F-D73D8F06EA70Q37248854-59E27062-821D-4C30-A60C-CF73515C6EC6Q37422674-092D3046-D3A3-47B8-9531-458659B6780CQ37579896-196C4806-ABC2-4520-AC19-C6A938188E53Q37612901-531FF35A-E954-4D10-8434-DE760DC837CAQ37627001-ADDC0B00-7BDB-44FD-A51D-7F9DA93540E7Q37701054-6D321571-E84F-4423-8E9A-33B01F7FB22B
P2860
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@ast
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@en
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@en-gb
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@nl
type
label
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@ast
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@en
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@en-gb
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@nl
prefLabel
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@ast
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@en
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@en-gb
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@nl
P2860
P921
P3181
P356
P1433
P1476
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001
@en
P2093
Emily E Scott
Natasha M DeVore
P2860
P2888
P3181
P356
10.1038/NATURE10743
P407
P577
2012-02-02T00:00:00Z
P5875
P6179
1034289210